Cargando…
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan
Sarcopenia is associated with poor prognosis of patients with hepatocellular carcinoma (HCC). We investigated the association of skeletal muscle volume (SMV) and its change in HCC patients taking lenvatinib. In 130 HCC patients, psoas mass index (PMI) was calculated as the left–right sum of the majo...
Autores principales: | Fujita, Masashi, Abe, Kazumichi, Kuroda, Hidekatsu, Oikawa, Takayoshi, Ninomiya, Masashi, Masamune, Atsushi, Okumoto, Kazuo, Katsumi, Tomohiro, Sato, Wataru, Iijima, Katsunori, Endo, Tetsu, Fukuda, Shinsaku, Tanabe, Nobukazu, Numao, Hiroshi, Takikawa, Yasuhiro, Ueno, Yoshiyuki, Ohira, Hiromasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021276/ https://www.ncbi.nlm.nih.gov/pubmed/35444161 http://dx.doi.org/10.1038/s41598-022-10514-3 |
Ejemplares similares
-
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
por: Kuroda, Hidekatsu, et al.
Publicado: (2022) -
A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage
por: Ninomiya, Masashi, et al.
Publicado: (2023) -
Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
por: Endo, Kei, et al.
Publicado: (2020) -
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma
por: Kuorda, Hidekatsu, et al.
Publicado: (2019) -
Impact of the COVID‐19 pandemic on the performance of endoscopy in the Tohoku region of Japan
por: Iijima, Katsunori, et al.
Publicado: (2023)